Researchers at UT Southwestern Medical Heart led a research revealed in JAMA Community Open which discovered that particular chemotherapies are related to an elevated long-term...
The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
Trial membersWe carried out a global, part 1, multi-centre, single-arm, open-label trial (ClinicalTrials.gov identifier: NCT03177187, EudraCT: 2016-003141-28) at three centres in Europe (RMH...
ABSTRACTS: 57, 58
Two medical trials led by researchers from The College of Texas MD Anderson Most cancers Heart demonstrated early constructive outcomes from novel therapies...
